Abstract
Thioredoxin-1 Attenuates Early Graft Loss after Intraportal Islet Transplantation in Mice
Highlights
Since the development of the Edmonton protocol, islet transplantation has become an effective option for the clinical treatment of type 1 diabetic patients [1]
The present study demonstrates that overexpression of TRX on the islet grafts is not sufficient to improve engraftment
We propose that a combination of TRX and other anti-inflammatory treatments represents a promising regimen for improving the efficacy of islet transplantation
Summary
Since the development of the Edmonton protocol, islet transplantation has become an effective option for the clinical treatment of type 1 diabetic patients [1]. Several donor pancreases are still needed to cure each diabetic patient. The instant blood-mediated inflammatory reaction (IBMIR) that occurs as an innate immune response, characterized by activation of both the coagulation and complement cascades, is a major cause of islet graft loss [2,3,4]. We and others have demonstrated that tissue factor (TF) and monocyte chemoattractant protein-1 (MCP-1) expressed on the grafted islets elicit the IBMIR [4,5,6,7,8,9]. To achieve successful outcomes of islet transplantation from a single donor organ, avoidance of the IBMIR is necessary
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call